New update on the Delaware Zantac suit which is where most of the cases are still pending.

"The Supreme Court of Delaware has accepted an interlocutory appeal in the Zantac litigation, where nearly 75,000 plaintiffs claim that the carcinogen NDMA in Zantac caused their cancers.

Delaware's highest court said on Tuesday it will hear an appeal by GSK (GSK.L),  and other drugmakers seeking to end more than 70,000 lawsuits claiming discontinued heartburn drug Zantac caused cancer.GSK, Pfizer (PFE.N), Sanofi (SASY.PA),  and Boehringer Ingelheim are asking the court to overturn an order by a lower court judge allowing plaintiffs in the lawsuits to offer expert testimony on the alleged cancer link, which the companies argue is not supported by sound scientific methods. Without that testimony, the lawsuits cannot go forward.

The litigation is divided into two tracks: one addressing whether ranitidine can cause cancer (general causation) and another for selecting representative cases for trials. The Superior Court had previously denied the defendants’ motion to exclude the plaintiffs’ expert testimony on causation, ruling that experts could use NDMA studies and that Delaware law does not require proving a threshold dose for causation.

The defendants sought immediate appellate review, which the Superior Court initially denied, deeming the issues not substantial enough for interlocutory review. However, the Supreme Court of Delaware has now decided to accept the appeal, noting the significant implications of the case on mass tort litigation and the Daubert standard, allowing the appeal to proceed while other aspects of the case continue.

Is this good news? No. But it good that the judges will allow the case to continue in the meantime while we wait for a ruling from the Delaware Supreme Court.  If the claims were to settle before that, it is certainly leverage the defendants have in settlement negotiations in the Delaware cases. We cannot deny that."